"The fact that the fruits of this collaboration are so far into the future is one of the reasons the market hasn’t reacted favorably to the deal, IMO. (Dilution, of course, is another reason.)
GTC needs to ink more Merrimack-like supply deals."
I do not agree with you. Any deal aiming at the development of a new product will take the time this deal takes. Also the deal with Merrimack has taken and still will take its time. You may argue that a Merrimack-like deal will give GTCB milestone payments in an early stage, but you can have several and different deals at the same time. I am sure that GTCB will close supply deals in the coming years, hopefully with those companies, which have their goats already grazing at GTCB's farm (Centocor (2 products), Abbot (Humira)), and other ones which will bet on transgenic goats as a new platform.
This deal is IMO above all important, since it shakes up the blood plasma industry and opens up an array of new opportunities in that field in collaboration with LBF, at good terms. At the same time, GTCB is giving itself the financial stability it needs right now, without running the risk that the shares issued will be immediately dumped on the market. By stabilizing its financial position it substantially improves its position at the negotiation table with potential partners for Atryn in the US and that by itself may be translated into an important pay-back of the LBF-deal in the short term.
What the market thinks, I don't know. I am still waiting for the market to start thinking. If the market was capable of thinking, we would have seen a reflection of that soon after the approval of Atryn, but nothing. At least this deal may give a new kick-start to the thinking process.
AI
Market Data 
Markets 
